Payment overview · 2025
General Payments
$362.31
14 reported records · 5 companies
Healthcare provider profile · identity verified
Nong Chrang, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SOMERSWORTH, NH · NPI 1043673379
Verified facts
What the public records show
CMS Open Payments records show Nong Chrang, FNP received $362.31 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 68.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $246.69 | 68.1% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.40 | 12.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.31 | 6.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.05 | 6.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.86 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $362.31 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $152.89 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $143.40 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 502 | 144 |
| Lisinopril | Lisinopril | 315 | 92 |
| Gabapentin | Gabapentin | 243 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 234 | 57 |
| Lorazepam | Lorazepam | 230 | 49 |
| Losartan Potassium | Losartan Potassium | 196 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 172 | 57 |
| Alprazolam | Alprazolam | 171 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 48 |
| Omeprazole | Omeprazole | 153 | 47 |
| Oxycodone Hcl | Oxycodone Hcl | 146 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 36 |
| Furosemide | Furosemide | 129 | 38 |
| Metformin Hcl Er | Metformin Hcl | 125 | 36 |
| Simvastatin | Simvastatin | 121 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 35 |
| Tramadol Hcl | Tramadol Hcl | 114 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 26 |
| Metformin Hcl | Metformin Hcl | 106 | 31 |
| Prednisone | Prednisone | 105 | 50 |
| Potassium Chloride | Potassium Chloride | 98 | 25 |
| Sertraline Hcl | Sertraline Hcl | 98 | 30 |
| Clonazepam | Clonazepam | 94 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 88 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 85 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 21 |
| Atenolol | Atenolol | 75 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 23 |
| Diazepam | Diazepam | 74 | 13 |
| Glimepiride | Glimepiride | 70 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 14 |
| Eliquis | Apixaban | 56 | 18 |
| Lovastatin | Lovastatin | 55 | 13 |
| Nystatin | Nystatin | 52 | 23 |
| Montelukast Sodium | Montelukast Sodium | 51 | 14 |
| Ibuprofen | Ibuprofen | 48 | 12 |
| Allopurinol | Allopurinol | 46 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 13 |
| Ezetimibe | Ezetimibe | 44 | 15 |
| Bupropion Xl | Bupropion Hcl | 42 | 12 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Meloxicam | Meloxicam | 41 | 11 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 40 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 40 | suppressed |
| Carvedilol | Carvedilol | 39 | 12 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Fluconazole | Fluconazole | 38 | 17 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 37 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | 12 |
| Chlorthalidone | Chlorthalidone | 33 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Ozempic | Semaglutide | 31 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 14 |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $362.31 · 14 records | ABBVIE INC. | AIRSUPRA, BREZTRI, MOUNJARO, QULIPTA, RELISTOR, TRULANCE, UBRELVY, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error